Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
European Journal of Cancer2021Vol. 157, pp. 361–372
Citations Over TimeTop 10% of 2021 papers
Yoshiyasu Umeda, Shusuke Yoshikawa, Yukiko Kiniwa, Takeo Maekawa, Osamu Yamasaki, Taiki Isei, Shigeto Matsushita, Motoo Nomura, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Tatsuya Takenouchi, Ryo Tanaka, Hiroshi Kato, Atsushi Otsuka, Taisuke Matsuya, Natsuki Baba, Kotaro Nagase, Takashi Inozume, T Onuma, Yutaka Kuwatsuka, Noriki Fujimoto, Takahide Kaneko, Masazumi Onishi, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Nakamura
Related Papers
- → Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC(2019)20 cited
- → Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up(2016)30 cited
- → Combination boosts survival for metastatic melanoma(2014)
- P3-23-12 婦人科がん患者における再発後生存期間(post progression survival:PPS)と全生存期間(overall survival:OS)および無増悪生存期間(progression-free survival:PFS)との関連(Group88 悪性腫瘍全般・その他治療,一般演題,公益社団法人日本産科婦人科学会第68回学術講演会)(2016)
- → Exploratory analysis of multiprotein serum predictors at baseline of progression-free survival of ipilimumab or ipilimumab and nivolumab in the Checkmate-069 study.(2017)